Study guide

10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor

Key Takeaways Explain This Topic AI

Placental Abruption presents with painful dark red bleeding, a rigid woody uterus, fetal distress, and high DIC risk; Placenta Previa presents with painless bright red bleeding and a soft non-tender uterus.

Digital vaginal exams are strictly contraindicated in Placenta Previa due to the risk of tearing placental vessels and precipitating fatal hemorrhage.

Preterm labor tocolysis (Magnesium sulfate, Terbutaline, Nifedipine, Indomethacin) is used to delay delivery by 48 hours to allow Betamethasone (12 mg IM x 2 doses) to accelerate fetal lung maturity.

Uterine atony accounts for 70-80% of postpartum hemorrhage (PPH); management includes bimanual fundal massage, Oxytocin infusion, Methergine, Hemabate, Misoprostol, and TXA.

Methylergonovine (Methergine) is contraindicated in hypertension; Carboprost (Hemabate) is contraindicated in asthma.

Last updated: July 2026

  • 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor
  • Placental Abruption vs. Placenta Previa

Third-trimester vaginal bleeding is a critical obstetric emergency. The two primary causes— Placental Abruption and Placenta Previa —have distinct pathophysiological mechanisms, clinical presentations, and management mandates. [ THIRD-TRIMESTER OBSTETRIC BLEEDING ]

  • │
  • ┌─────────────────────────────┴─────────────────────────────┐
  • ▼ ▼
  • [ PLACENTAL ABRUPTION ] [ PLACENTA PREVIA ]
  • Premature Placental Separation - Placenta Implanted Over Cervical Os
  • Dark Red, PAINFUL Bleeding - Bright Red, PAINLESS Bleeding
  • RIGID, "Woody", Tender Uterus - SOFT, Non-Tender Uterus
  • Uterine Hypertonus / Contractions - No Uterine Hypertonus
  • Fetal Distress / Late Decelerations - Normal Fetal Heart Rate (Initially)

- High Risk of DIC (Tissue Factor) - Digital Vaginal Exam CONTRAINDICATED!

Detailed Comparison Table

Diagnostic Feature Placental Abruption (Abruptio Placentae) Placenta Previa

Pathophysiology Premature separation of placenta from uterine wall before delivery Implantation of placenta over or near the internal cervical os

Abdominal Pain Severe, constant, painful abdominal/back pain Painless (unless concurrent active labor)

Bleeding Characteristics Dark red , clotted bleeding; can be concealed behind placenta (20% concealed) Bright red , fresh overt vaginal bleeding

Uterine Physical Exam Rigid, "woody," hypertonic , and exquisitely tender uterus Soft, relaxed, non-tender uterus

Fetal Assessment Fetal distress common (bradycardia, late decelerations, loss of variability) Fetal heart rate usually reassuring initially unless maternal hypovolemia occurs

Systemic Complications High risk of Disseminated Intravascular Coagulation (DIC) due to tissue factor release Maternal hypovolemic shock if hemorrhage is massive

Digital Vaginal Exam Safe after ruling out previa STRICTLY CONTRAINDICATED (risk of fatal disruption of placental tissue)

Uterine Rupture

Uterine rupture is a catastrophic obstetric emergency involving full-thickness tearing of the uterine wall, leading to expulsion of fetal parts into the peritoneal cavity and rapid maternal-fetal exsanguination.

Risk Factors

Prior Cesarean section delivery (especially classical vertical uterine incision).

Trial of Labor After Cesarean (TOLAC).

Prior myomectomy or uterine surgery.

High parity and excessive, unmonitored oxytocin administration.

Obstructed labor or fetal malpresentation.

Clinical Presentation & Critical Signs

Sudden, severe, sharp "tearing" abdominal pain occurring at the peak of a contraction.

Sudden cessation of uterine contractions (uterine muscle torn apart).

Breakthrough abdominal pain despite adequate epidural anesthesia.

Loss of fetal station: Presenting fetal part slips backward out of the pelvis and is no longer palpable on vaginal exam.

Palpable fetal parts directly beneath the maternal abdominal wall.

Severe fetal bradycardia or terminal late decelerations .

Rapid progression to maternal hypovolemic shock. Immediate surgical laparotomy and emergency delivery are mandatory.

Preterm Labor & Tocolytic Therapy

Preterm labor (PTL) is defined as regular uterine contractions resulting in cervical change prior to 37 + 0 37^{+0} 3 7 + 0 weeks gestation. The primary objective of tocolytic therapy is not to prevent delivery indefinitely, but to delay delivery for 48 hours so that antenatal corticosteroids can be administered to accelerate fetal pulmonary maturity, and to allow safe transfer of the patient to a tertiary neonatal intensive care unit (NICU).

Tocolytic Agents in Critical Care Transport

Drug Class & Agent Mechanism of Action Transport Dosing Protocol Maternal & Fetal Considerations Contraindications

Magnesium Sulfate Antagonizes calcium intracellular entry in myometrium 4 g 4 \text{ g} 4 g IV load over 20 min, then 1 – 2 g/hr 1–2 \text{ g/hr} 1–2 g/hr IV infusion. Dual benefit: tocolysis AND neuroprotection against cerebral palsy for fetuses < 32 <32 < 32 weeks. Myasthenia gravis, renal failure, cardiac block.

Terbutaline Selective β 2 \beta_2 β 2 ​ -adrenergic receptor agonist 0.25 mg 0.25 \text{ mg} 0.25 mg SC subcutaneously every 20–30 min (up to 3 doses). Causes maternal/fetal tachycardia, anxiety, hyperglycemia, hypokalemia, and pulmonary edema. Maternal heart disease, severe hyperthyroidism, uncontrolled diabetes.

Nifedipine L-type Calcium Channel Blocker 20 mg 20 \text{ mg} 20 mg PO orally load, then 10 – 20 mg 10–20 \text{ mg} 10–20 mg PO q4-6h. Direct smooth muscle relaxation. Well tolerated; monitor maternal BP. Maternal hypotension (SBP < 90 mmHg <90 \text{ mmHg} < 90 mmHg ), aortic stenosis.

Indomethacin Cyclooxygenase (COX) inhibitor (decreases prostaglandins) 50 mg 50 \text{ mg} 50 mg PO/PR load, then 25 mg 25 \text{ mg} 25 mg PO q6h for max 48 hours. Only used at < 32 <32 < 32 weeks gestation . Prolonged use ( > 48 h >48\text{h} > 48 h ) causes premature closure of fetal ductus arteriosus and oligohydramnios. Peptic ulcer disease, renal impairment, gestational age ≥ 32 \ge 32 ≥ 32 weeks.

Antenatal Corticosteroid Therapy

Antenatal corticosteroids are administered to all pregnant women between 24 + 0 24^{+0} 2 4 + 0 and 34 + 0 34^{+0} 3 4 + 0 weeks gestation who are at risk of preterm delivery within 7 days.

Betamethasone Protocol: 12 mg 12 \text{ mg} 12 mg IM (intramuscularly) in two doses administered 24 hours apart .

Dexamethasone Protocol: 6 mg 6 \text{ mg} 6 mg IM every 12 hours for a total of 4 doses .

Physiological Effect: Corticosteroids cross the placenta and stimulate fetal type II pneumocytes to produce alveolar surfactant , improving lung compliance.

Clinical Impact: Dramatically reduces the incidence and severity of neonatal Respiratory Distress Syndrome (RDS) , Intraventricular Hemorrhage (IVH) , Necrotizing Enterocolitis (NEC) , and overall neonatal mortality.

Uterine Atony & Postpartum Hemorrhage (PPH)

Postpartum Hemorrhage (PPH) is historically defined as blood loss ≥ 500 mL \ge 500 \text{ mL} ≥ 500 mL after vaginal delivery or ≥ 1000 mL \ge 1000 \text{ mL} ≥ 1000 mL after C-section, but updated ACOG guidelines define PPH as cumulative blood loss ≥ 1000 mL \ge 1000 \text{ mL} ≥ 1000 mL or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours post-birth.

The 4 Ts of PPH Etiology

Tone: Uterine Atony (accounts for 70–80% of all PPH cases).

Trauma: Vaginal, cervical, or uterine lacerations.

Tissue: Retained placenta or blood clots.

Thrombin: Coagulopathy (pre-existing or secondary to DIC).

  • Stepwise Emergency Management Protocol [ DIAGNOSIS OF POSTPARTUM HEMORRHAGE (PPH ≥ 1000 mL) ]
  • │
  • ▼
  • [ 1. BIMANUAL FUNDAL MASSAGE ]
  • │
  • ▼
  • [ 2. FIRST-LINE DRUG: OXYTOCIN (PITOCIN) ]
  • (10-40 units in 1L LR Infusion or 10 units IM)
  • │
  • ▼
  • ┌──────────────────────────────┴──────────────────────────────┐
  • ▼ ▼
  • [ PATIENT HAS HYPERTENSION? ] [ PATIENT HAS ASTHMA? ]
  • │ │
  • ┌───────────┴───────────┐ ┌───────────┴───────────┐
  • ▼ ▼ ▼ ▼
  • YES NO YES NO
  • (AVOID Methergine) (Give Methergine 0.2mg IM) (AVOID Hemabate) (Give Hemabate 250mcg IM)
  • │ │ │ │
  • └───────────┬───────────┘ └───────────┬───────────┘
  • │ │
  • └──────────────────────────────┬──────────────────────────────┘
  • │
  • ▼
  • [ 3. SECONDARY AGENTS & ANTIFIBRINOLYTIC ]
  • Misoprostol (Cytotec) 800-1000 mcg PR
  • Tranexamic Acid (TXA) 1 g IV over 10 min

Bimanual Uterine Fundal Massage: Immediately insert one gloved hand into the vagina forming a fist against the anterior uterine wall, while the external hand massages the posterior uterine fundus through the abdomen to stimulate myometrial contraction.

Oxytocin (Pitocin): First-line agent.

Dosing: Add 10 – 40 units 10–40 \text{ units} 10–40 units to 1000 mL 1000 \text{ mL} 1000 mL Lactated Ringer's or Normal Saline; infuse at 125 – 250 mL/hr 125–250 \text{ mL/hr} 125–250 mL/hr IV. Alternatively, give 10 units 10 \text{ units} 10 units IM.

CRITICAL SAFETY WARNING: NEVER give Oxytocin as an IV push bolus! Direct IV push causes severe vascular smooth muscle relaxation, leading to sudden hypotension, reflex tachycardia, dysrhythmias, and cardiac arrest.

Methylergonovine (Methergine): Ergot alkaloid.

Dosing: 0.2 mg 0.2 \text{ mg} 0.2 mg IM every 2–4 hours.

ABSOLUTE CONTRAINDICATION: Hypertension, Preeclampsia, or Eclampsia. Methergine produces intense vasoconstriction that can precipitate hypertensive emergency, stroke, or myocardial infarction.

Carboprost Tromethamine (Hemabate): Synthetic prostaglandin F 2 α F_{2\alpha} F 2 α ​ .

Dosing: 250 mcg 250 \text{ mcg} 250 mcg IM (or intramyometrial) every 15–90 minutes (max total dose 2 mg 2 \text{ mg} 2 mg / 8 doses).

ABSOLUTE CONTRAINDICATION: Asthma. Hemabate causes potent bronchial smooth muscle constriction, resulting in severe bronchospasm and hypoxic respiratory failure.

Misoprostol (Cytotec): Synthetic prostaglandin E 1 E_1 E 1 ​ .

Dosing: 800 – 1000 mcg 800–1000 \text{ mcg} 800–1000 mcg rectally (PR) or 600 mcg 600 \text{ mcg} 600 mcg sublingually. Safe in hypertensive and asthmatic patients.

Tranexamic Acid (TXA): Antifibrinolytic agent.

Dosing: 1 g 1 \text{ g} 1 g IV in 100 mL 100 \text{ mL} 100 mL NS over 10 minutes administered within 3 hours of birth. A second 1 g 1 \text{ g} 1 g dose is given if bleeding continues after 30 minutes.